Research has shown that the gut microbiota plays a role in systemic lupus erythematosus (SLE) pathogenesis, with studies indicating that imbalances in gut bacteria, such as increased levels of Rummunococcus gnavus and reduced levels of Lactobacillaceae, may exacerbate the disease. Previous studies have demonstrated that prebiotics and probiotics can help modulate gut microbiota and improve intestinal health, suggesting potential therapeutic benefits for patients with SLE.
In this study, the effects of Hirsutella sinensis polysaccharides and P. goldsteinii probiotics were evaluated in a mouse model of SLE induced by imiquimod. Results showed that both interventions reduced the severity of lupus symptoms, including proteinuria and serum anti-DNA autoantibodies, as well as markers of kidney and liver function. Despite these improvements in autoimmune response and organ function, no significant changes were observed in gut barrier integrity or microbiota composition. The study suggests that these prebiotics and probiotics may serve as complementary strategies for managing SLE symptoms by modulating immune responses, although further clinical trials are needed to confirm these findings in humans.
Reference: Chang SH, Ko YF, Liau JC, et al. Hirsutella sinensis polysaccharides and Parabacteroides goldsteinii reduce lupus severity in imiquimod-treated mice. Biomed J. 2024 Jun 18:100754. doi: 10.1016/j.bj.2024.100754. Epub ahead of print. PMID: 38901796.
